Pierre Fabre Pharmaceuticals Initiates Phase IIa Clinical Trial Programme for F17464 in Schizophrenia

Pierre Fabre Pharmaceuticals has announced the initiation of a Phase IIa clinical trial programme for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The 6-week multinational European trial will enroll 142 patients.

This development is a reflection of Pierre Fabre Laboratories’ strategy to invest in R&D on priority franchises such as neuropsychiatry, oncology and dermatology.

Pierre Fabre Pharmaceuticals laboratories’ candidate medication, F17464, is a potent oral selective D3 antagonist/5-HT1A partial agonist. It is currently being developed for the treatment of schizophrenia.

"After the marketing authorisation issued in 2013 by the FDA to Forest Laboratories, now Actavis, for Fetzima -levomilnacipran, an active compound discovered by the Pierre Fabre Research Institute, we welcome this new step with another molecule from our R&D experts' research into the central nervous system. The originality of this new molecule and the initial pharmacodynamics and safety results are extremely encouraging," declared Frédéric Duchesne, President of Pierre Fabre Pharmaceuticals.